<DOC>
	<DOC>NCT01392326</DOC>
	<brief_summary>This study will assess the efficacy and safety of secukinumab in patients with active psoriatic arthritis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.</brief_summary>
	<brief_title>Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria: Male or nonpregnant, nonlactating female patients at least 18 years of age Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each) Rheumatoid factor and antiCCP antibodies negative Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥2cm diameter or nail changes consistent with psoriasis or documented history o plaque psoriasis Exclusion criteria: Chest Xray with evidence of ongoing infectious or malignant process Subjects who have previously been treated with more than 3 different TNFα inhibitors Subjects taking high potency opioid analgesics Subjects who have ever received biologic immunomodulating agents except for those targeting TNFα Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>PsA</keyword>
	<keyword>ACR</keyword>
	<keyword>CASPAR</keyword>
</DOC>